The Biotinylated Anti-PSCA Antibody (HDLA049) is a highly specific antibody designed for research involving Prostate Stem Cell Antigen (PSCA), a cell surface marker associated with prostate cancer. This antibody, raised in rabbits, is validated for use in immunohistochemistry and is highly reactive with human samples. It binds specifically to the PSCA protein, allowing for accurate detection and analysis in various cell types.PSCA is a protein that plays a crucial role in prostate cancer progression and metastasis, making it a valuable target for cancer research.
Understanding the expression and function of PSCA is essential for developing targeted therapies and diagnostic tools for prostate cancer patients. The Biotinylated Anti-PSCA Antibody provides researchers with a reliable tool for studying PSCA and its implications in cancer biology, potentially leading to advancements in cancer treatment strategies.
Product Code:
HDLA049
Size:
100 µg
Clonality:
Monoclonal
Clone:
DM87
Synonyms:
PSCA,UNQ206,PRO232
Applications:
ELISA, Flow Cyt
Recommended Dilution:
ELISA 1:5000-10000; Flow Cyt 1:100
Host Species:
Rabbit
Isotype:
Rabbit IgG
Reactivity:
Human
Purification Method:
Purified from cell culture supernatant by affinity chromatography
Formulation:
Powder
Buffer:
1XPBS
Storage:
Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing).Lyophilized antibodies are shipped at ambient temperature.
Usage:
Research use only
Background:
This gene encodes a glycosylphosphatidylinositol-anchored cell membrane glycoprotein. In addition to being highly expressed in the prostate it is also expressed in the bladder, placenta, colon, kidney, and stomach. This gene is up-regulated in a large proportion of prostate cancers and is also detected in cancers of the bladder and pancreas. This gene includes a polymorphism that results in an upstream start codon in some individuals; this polymorphism is thought to be associated with a risk for certain gastric and bladder cancers. Alternative splicing results in multiple transcript variants.
